Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03268356
Other study ID # PST-HK-100.1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 15, 2017
Est. completion date December 31, 2020

Study information

Verified date November 2022
Source AgNovos Healthcare, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the procedure and safety profile of the AGN1 Femoral LOEP Kit. This pilot study will be used to evaluate AGN1 Femoral LOEP treatment in a contralateral proximal femur during hip fracture repair.


Description:

The research will be conducted as a prospective single-center study within Hong Kong. The maximum number of subjects to be treated is twenty (20). This will be a non-randomized and non-blinded study. Subjects having had a fragility hip fracture on one side will be treated with LOEP in the contralateral non-fractured proximal femur in the same operative session as the surgical repair of the fractured hip. A fragility fracture is defined as a fracture resulting from a fall from standing height. All subjects will undergo hip fracture repair as recommended by the treating orthopedic surgeon. Repair may include nailing, plates, screws and hip prosthesis. Subjects may continue to receive, or when appropriate, can be commenced on a treatment regime for osteoporosis. This decision will be made by the treating physician who will determine the best course of action for each patient. The outcome of this decision will have not affect the patient's eligibility for this trial. Follow-up visits will be conducted at three (3) months, six (6) months, twelve (12) months, and twenty-four (24) months after the procedure.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Subject is a postmenopausal female 2. Subject has a low-energy fragility hip fracture in one hip and will undergo surgical repair of the fractured hip. 3. Subject is = 65 years of age. 4. Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full duration of the study. 5. Subject is capable of giving written informed consent to participate in the study. Exclusion Criteria: 1. Subject has a prior diagnosis of secondary osteoporosis. 2. Subject has history of any hip surgery or previous hip fracture in the non-fractured hip. 3. Subject has progressive increase in undiagnosed hip pain over the previous six (6) months that in the opinion of the Investigator may suggest other underlying bone or joint pathology (e.g. osteoarthritis, fracture, etc.). 4. Subject has serum calcium levels outside the normal lab range as per local guidelines and reference ranges. 5. Subject has moderate to severe renal insufficiency as per local guidelines and reference ranges. 6. Subject has insulin-dependent diabetes mellitus (IDDM). 7. Subject has Body Mass Index (BMI) > 30. 8. Subject exhibits excessive smokeless tobacco use or excessive smoking as determined by the principal investigator*. 9. Subject exhibits excessive alcohol consumption as determined by the principal investigator*. 10. Subject has radiological evidence of gross bony or joint pathology of the non-fractured hip. 11. Subject treated with corticosteroids or systemic glucocorticoids for ten (10) days in the previous six (6) months. 12. Subject has history of oral or parenteral use of immune-suppressive drugs in the previous twelve months. 13. Subject has history of metabolic bone disease other than osteoporosis (eg. Paget's disease). 14. Subject has a history of auto-immune arthritic diseases including rheumatoid, psoriatic, or those associated with systemic lupus erythematosus, spondyloarthropathy, Reiter's Syndrome or Crohn's Disease. 15. Subject has a history of radiation therapy to the hip or pelvic region. 16. Subject has history of chemotherapy treatment for any condition within the previous five years. 17. Subject has history of any diagnosis and treatment of malignancies (excluding basal cell carcinoma) within the previous five years. 18. Subject has known allergies to implanted device. 19. Subject has severe comorbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate. 20. Subject is currently enrolled in another clinical study.

Study Design


Intervention

Device:
AGN1 Femoral Local Osteo-Enhancement Procedure Kit
A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.

Locations

Country Name City State
Hong Kong Queen Mary Hospital - Department of Orthopaedics and Traumatology Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
AgNovos Healthcare, LLC

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment or Device Emergent Serious Adverse Events Incidence of all serious adverse events (SAEs) occurring from the day of procedure through the twenty-four (24) month follow-up period determined to be definitely related to Femoral LOEP and/or the AGN1 device. 24 Months
Secondary Incidence of Non-Treatment Emergent Fragility Fractures Incidence of fragility fractures unrelated to the device or procedure occurring during the follow-up period. 24 Months
Secondary Incidence of Treatment or Device Emergent Adverse Events Incidence of all adverse events occurring from the day of procedure through the twenty-four (24) month follow-up determined to be definitely related to Femoral LOEP and/or the AGN1 device. 24 Months
Secondary Change in Bone Mineral Density between Baseline and 12 Months Evaluation of bone mineral density (BMD) post-procedure at twelve (12) months. 12 Months
Secondary Change in Bone Mineral Density between Baseline and 24 Months Evaluation of bone mineral density (BMD) post-procedure at twenty-four (24) months. 24 Months
See also
  Status Clinical Trial Phase
Completed NCT02507609 - Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium N/A
Completed NCT03906864 - Care Pathway for Sub-acute Hip Rehabilitation N/A
Recruiting NCT04063891 - Vibration Therapy as an Intervention for Enhancing Trochanteric Hip Fracture Healing in Elderly Patients N/A
Completed NCT05039879 - Life Improving Factors After a Hip Fracture
Not yet recruiting NCT03887494 - Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY) N/A
Terminated NCT03065101 - Trigen InterTAN vs Sliding Hip Screw RCT N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Completed NCT03545347 - Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture. Phase 2
Recruiting NCT05971173 - Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery Early Phase 1
Active, not recruiting NCT04957251 - Anterior vs Posterior Approach for Hip Hemiarthroplasty N/A
Terminated NCT04372966 - Uncemented Versus Cemented Total Hip Arthroplasty for Displaced Intracapsular Hip Fractures N/A
Withdrawn NCT05030688 - Fascia Iliaca Compartment Block and PENG Block for Hip Arthroplasty N/A
Completed NCT04424186 - 'Rehabilitation for Life' N/A
Not yet recruiting NCT04183075 - Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture N/A
Withdrawn NCT05518279 - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures Phase 3
Not yet recruiting NCT02892968 - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients N/A
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Active, not recruiting NCT02247791 - Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty N/A
Completed NCT00746876 - Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures. N/A
Completed NCT00058864 - The HIP Impact Protection Program (HIP PRO) N/A

External Links